Immuneering (IMRX) Stock Statistics & Valuation Metrics

Immuneering has a market cap or net worth of $49.66M. The enterprise value is $36.33M.

Immuneering has 35,985,703 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immuneering’s return on equity (ROE) is -1.47 and return on invested capital (ROIC) is -141.72%.

The current PE Ratio of Immuneering is >-0.01. Immuneering’s PEG ratio is >-0.01.

In the last 12 months, Immuneering had revenue of 0.00 and earned -61.04B in profits. Earnings per share was -2.04K.

In the last 12 months, operating cash flow was -55.00M and capital expenditures -84.88K, giving a free cash flow of -55.08M billion.

Immuneering pays an annual dividend of ―, resulting in a dividend yield of ―

Immuneering upcoming earnings date is May 13, 2025, TBA Not Confirmed.

Immuneering as a current ratio of 5.28, with Debt / Equity ratio of 10.06%

In the past 12 months, Immuneering has paid 0.00 in taxes.

Immuneering EV to EBITDA ratio is 0.50, with an EV/FCF ratio of 579.40.

Immuneering has $36.14M in cash and marketable securities with $4.16M in debt, giving a net cash position of -$31.98M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Immuneering is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy